Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.73 |
| ▸ | LMNA | P02545 | 6/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 6/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4979105 | 0.93 | HSP90AB1 (0.62) | HSP90AB1LMNAPOLBMAPTTP53 | |
| SCHEMBL4975134 | 0.90 | LMNA (0.76) | HSP90AB1LMNAPOLBMAPTTP53 | |
| SCHEMBL4981551 | 0.90 | HSP90AB1 (0.61) | HSP90AB1LMNAPOLBMAPTTP53 | |
| SCHEMBL4978638 | 0.89 | LMNA (0.59) | HSP90AB1LMNAPOLBMAPTTP53 | |
| SCHEMBL4980313 | 0.89 | HSP90AB1 (0.60) | HSP90AB1LMNAPOLBMAPTTP53 | |
| SCHEMBL4974739 | 0.87 | LMNA (0.60) | HSP90AB1LMNAPOLBMAPTTP53 | |
| SCHEMBL14346583 | 0.86 | LMNA (0.58) | HSP90AB1LMNAPOLBMAPTTP53 | |
| SCHEMBL4976885 | 0.85 | LMNA (0.57) | HSP90AB1LMNAPOLBMAPTTP53 | |
| SCHEMBL4976228 | 0.85 | LMNA (0.60) | HSP90AB1LMNAPOLBMAPTTP53 | |
| SCHEMBL4974757 | 0.84 | HSP90AB1 (0.57) | HSP90AB1LMNAPOLBMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| WO-2007146122-A2 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | HRH3, HRH4, HRH2 | HSP90AB1 2652/4885LMNA 4534/4885POLB 1658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.